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Both tumor hypoxia and dysregulated metabolism are classical features of cancer. Recent analyses have revealed
complex interconnections between oncogenic activation, hypoxia signaling systems and metabolic pathways that
are dysregulated in cancer. These studies have demonstrated that rather than responding simply to error signals
arising from energy depletion or tumor hypoxia, metabolic and hypoxia signaling pathways are also directly
connected to oncogenic signaling mechanisms at many points. This review will summarize current understanding
of the role of hypoxia inducible factor (HIF) in these networks. It will also discuss the role of these interconnected
pathways in generating the cancer phenotype; in particular, the implications of switching massive pathways that
are physiologically ‘hard-wired’ to oncogenic mechanisms driving cancer.
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Altered energy metabolism is a classical feature of cancer
that underpins the diagnostic use of labeled fluorodeoxy-
glucose in positron emission tomography (FDG-PET) and
is the focus of major efforts to define new therapeutic ap-
proaches to the disease. In normal cells, glucose is con-
verted through the Embden-Meyerhof glycolytic pathway
to pyruvate, which is then predominantly fed into the
mitochondrion for ATP production. Cancer cells exhibit
an enhanced capacity to ‘ferment’ glucose to pyruvate and
then lactate, even in the presence of sufficient oxygen to
support mitochondrial metabolism. This effect was first
described almost 90 years ago by Warburg, who became
convinced that the primary defect was in mitochondrial
function, famously stating (of cancer) ‘the respiration is
always disturbed inasmuch as it is incapable of causing
the disappearance of the fermentation’ [1]. Later reviewers
of the controversy have puzzled over why Warburg appar-
ently held this view so firmly, particularly as it was not
clearly supported by his own data on oxygen uptake [2].
More in keeping with current thinking, Warburg also
stated of glycolysis that it ‘furnishes, to our mind, the* Correspondence: pjr@well.ox.ac.uk
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article, unless otherwise stated.driving forces of growth’ [3]. However, it became clear,
not only that mitochondrial capacity in many cancers
is broadly comparable with normal tissue, but that up-
regulation of glycolysis is not universal in cancer [2].
Studies of experimental tumors revealed that aerobic
glycolysis was not greatly elevated in slow growing tu-
mors, despite their potential to metastasize and kill the
host, but was strongly associated with poorly differenti-
ated rapid growing variants. This change was revealed
to be strikingly associated with a shift in gene expression
to particular enzyme isoforms that are characteristic of
fetal tissues [4,5].
Despite these observations, in the latter part of the
20th century, the focus on metabolism in cancer was
overshadowed by genetic insights into oncogenesis that
implicated molecules directly involved in the regulation of
the cell cycle, DNA repair, growth, apoptosis and related
processes. It also became clear that the metabolic dysregu-
lation described by Warburg was not entirely specific for
cancer, being observed, for instance, in dividing cells in
immune activation [6,7]. Although this led to the refocus-
ing of cancer research on oncogene and tumor suppressor
pathways that had been identified genetically, there has
been a major resurgence of interest in understanding
metabolic pathways in cancer, including the mechanismsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tumor development and whether this offers a route to
treatment.
Alongside metabolic alterations, tumor hypoxia and
activation of hypoxia signaling pathways have consist-
ently been identified as features that are strongly asso-
ciated with aggressive malignancy. Hypoxia inducible
factor (HIF) has been defined as the key transcription
factor mediating responses to hypoxia, and HIF target
genes overlap strongly with those implicated in dysreg-
ulated tumor metabolism. This review will focus on the
interfaces between the HIF system and metabolic alter-
ations in cancer and on the implications of activating
complex, interconnected, hypoxia and metabolic signaling
pathways for the cancer phenotype.
The HIF hydroxylase system
Hypoxia inducible factor-1 (HIF-1) was first identified
as a transcriptional regulator that is bound to the hypoxia-
response element of the erythropoietin gene [8]. It was ini-
tially believed that the underlying oxygen sensing apparatus
was restricted to the regulation of erythropoietin. However,
early studies of the hypoxia-response element unexpectedly
indicated that the response pathway operated much more
widely [9]. It subsequently became clear that HIF-1 has
a wide range of other transcriptional targets, the first to
be identified being genes encoding a range of glycolytic
enzymes [10,11]. Interestingly, these studies revealed that
regulation by HIF was specific to particular enzyme iso-
forms and that the isoform-specific pattern of regulation by
HIF was strikingly similar to that which had been identified
earlier in analyses of the Warburg effect in cancer cells,
immediately raising a question as to the role of HIF in
metabolic alterations in cancer [12].
The HIF system itself has been reviewed extensively
elsewhere (for more detailed reviews see [13,14]). In outline,
HIF is a heterodimer of α and β subunits, both of which
are bHLH-PAS domain (basic-Helix-Loop-Helix Per-AHR/
ARNT/Sim) proteins. Three HIF-α isoforms exist (1α, 2α
and 3α), of which HIF-1α and HIF-2α are the best studied,
and form transcriptionally active heterodimers with HIF-
1β. Hypoxia inducible behavior is conferred by the HIF-α
subunits, the protein abundance and transcriptional activity
of which are regulated by oxygen-dependent prolyl and
asparaginyl hydroxylation respectively (Figure 1).
The most essential of these processes is HIF prolyl
hydroxylation, which exerts the most important control
over HIF activity in human cells, and is conserved in all
animal species. In higher animals, HIF prolyl hydroxylation
occurs at two sites (P402 and P564 in human HIF-1α).
Hydroxylation at these sites promotes association of HIF-α
polypeptides with the β-domain of von Hippel-Lindau
tumor suppressor (pVHL) E3 ligase, leading to the de-
struction of HIF-α by the ubiquitin-proteasome pathway.Though the two sites of prolyl hydroxylation can operate
independently, in native HIF-1α and HIF-2α molecules
these sites are hydroxylated sequentially and cooperate
to enhance the efficiency of pVHL-mediated proteolysis.
In a second regulatory pathway, asparaginyl hydroxylation
(N803 in human HIF-1α) reduces the activity of the
C-terminal transactivation domain (CAD), at least in part
by preventing recruitment of the p300/CBP co-activators
(reviewed in [13]).
These hydroxylations are all catalyzed by members of
the Fe(II) and 2-oxoglutarate (2-OG) dependent dioxygen-
ase superfamily (for reviews, see [15,16]). As dioxygenases,
the enzymes split molecular oxygen and incorporate both
atoms directly into their reaction products. The absolute
requirement for molecular oxygen as a substrate confers
sensitivity to hypoxia, though this may be modulated by
other factors. Oxidation of the prime substrate (HIF-α) is
coupled to the oxidative decarboxylation of 2-OG to suc-
cinate. Failure of the coupling process can leave the enzyme
in an inactive oxidized state and regeneration of the Fe(II)
catalytic center is then required for activity. This process is
proposed to be the basis of the dependency on the reducing
agent ascorbate, which is required to regenerate the active
Fe(II) enzyme. Co-ordination of the catalytic iron is
relatively labile, hence enzymes are iron-dependent and
catalysis is readily inhibited by iron chelators. In human
cells, HIF prolyl hydroxylation is catalyzed by three closely
related enzymes, PHD (prolyl hydroxylase domain) 1, 2 and
3 (otherwise known as EGLN 2, 1 and 3), while HIF
asparaginyl hydroxylation is catalyzed by a single enzyme,
FIH (factor inhibiting HIF). The multiple co-substrate and
co-factor requirements of these enzymes (2-OG, Fe(II) and
ascorbate, in addition to molecular oxygen) potentially
allow regulation of HIF activity by redox, metabolic and
hypoxic stimuli. In cancer, all these signals may contribute
to up-regulation of HIF pathways, by impairing the activity
of one or more of the HIF hydroxylases (Figure 2).
In addition, other interactions, which are not directly
connected with the oxygen sensing process, but which
modulate the HIF pathway through effects on the transcrip-
tion, translation, post-translational modification and protein
interactions of one or more HIF subunits, are also the
targets of oncogenic processes that up-regulate HIF in
cancer (Figure 2).
Up-regulation of hypoxia signaling pathways in cancer
Tumor hypoxia
Regions of profound hypoxia and necrosis are common
in solid tumors and their presence correlates with an
aggressive clinical course. Classical studies relating necrotic
regions of tumor to blood vessel disposition suggested that
tumor necrosis was, at least in part, driven by hypoxia [17].
More recently, this has been supported by the demonstra-
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Figure 1 Regulation of HIF-1 by oxygen dependent prolyl and asparaginyl hydroxylation of HIF-1α. Hypoxia inducible factor (HIF)-1α, a
basic-Helix-Loop-Helix Per-AHR/ARNT/Sim (bHLH-PAS) domain containing protein, contains three residues that are targets for regulatory
hydroxylation. P402 and P564 are targeted by the prolyl hydroxylase domain (PHD) enzymes (note that PHD3 can only hydroxylate P564) and
N803 by factor inhibiting HIF (FIH). P402 is located in the N-terminal, and P564 in the C-terminal, O2-dependent degradation domain. Prolyl
hydroxylated HIF-1α is recognized by the von Hippel-Lindau tumor suppressor (pVHL) E3 ligase complex, leading to degradation in normoxia.
Interestingly, prolyl and asparaginyl hydroxylation are differentially sensitive to hypoxia. Inhibition of prolyl hydroxylation alone (lower right) is
sufficient to allow HIF-1α to escape from pVHL E3-dependent proteolytic destruction and form an active transcriptional complex with HIF-β
through activity of the N-terminal activation domain (NAD). In more severe hypoxia, HIF-1α asparaginyl hydroxylation is also inhibited (lower left)
allowing recruitment of p300/CBP co-activators to its C-terminal transactivation domain (CAD), and enhancing the transcription of a specific set of
HIF-1 target genes. (HRE, hypoxia-response element).
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pattern of gene expression is absent in experimental tumors
that are genetically defective for HIF, clearly indicating that
it is driven by this pathway [19].
Given that HIF target genes include many of those
underpinning dysregulated tumor metabolism [20] and
that both tumor hypoxia [21] and the extent of dysregulated
metabolism [2,5] show clear correlations with aggressive
cancer phenotypes, it is tempting to conclude that activa-
tion of HIF pathways by tumor hypoxia itself is the major
cause of dysregulated tumor metabolism. However, a
number of observations reveal that the interconnections
are more complex. First, within solid tumors, regions of
hypoxia (assessed either by in vivo imaging or by use of
histochemical markers) show less co-incidence with regionsof HIF up-regulation than might be expected [22-24]. Sec-
ond, hematological malignancies that do not involve solid
tissue masses also manifest up-regulation of HIF [25,26].
Taken together these studies indicate that although micro-
environmental hypoxia clearly contributes to the activation
of HIF in cancer, other factors must also be important.
Metabolic regulation of HIF pathways
Multiple metabolic pathways impact on the regulation of
HIF, raising the possibility that in addition to HIF activation
driving dysregulated metabolism in cancer, dysregulated
metabolism promotes the activation of HIF. One possibility
is that altered 2-OG availability modulates HIF hydroxyl-
ation. In addition to its role in the Krebs cycle, 2-OG also







































Figure 2 Oncogenic signals act through multiple parallel pathways to activate HIF and its target genes. In addition to regulation by
hypoxia, hydroxylation of hypoxia inducible factor (HIF)-α may be influenced by metabolic and redox signals. In cancer, all of these
micro-environmental stresses can inhibit hydroxylation leading to accumulation of HIF. Oncogenic signals also impinge on the HIF pathway at
many other points, including transcription, translation, post-translational modification and pVHL-mediated degradation of HIF-α polypeptides. In
addition, oncogenic signals activate many HIF target genes directly.
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is the major amino group acceptor for transaminases. Thus,
2-OG would be well placed to act as a metabolic sensor
regulating HIF hydroxylase activity. In keeping with this,
reduced intracellular 2-OG in cultured cells depleted of
amino acids has recently been reported to reduce PHD
activity [27]. Unexpectedly, in this case, the regulation
of PHD activity had no effect on HIF-α protein levels,
but was reported to effect mTORC1 activation by amino
acids. The PHD enzymes were suggested to play a role
as metabolic sensors linking amino acid availability with
the mTORC1 pathway, although whether limiting 2-OG
availability modulates HIF hydroxylation in this setting
remains unclear.
Other Krebs cycle intermediates and endogenous organic
acid metabolites may also alter HIF hydroxylase activity
by competing with 2-OG at the catalytic site (fumarate
and succinate) or by product inhibition (succinate) [28,29].
In addition, in different assays, citrate, isocitrate, malate
and oxaloacetate have been reported to bind or inhibit
recombinant HIF hydroxylases. Different HIF hydroxylases
are differentially sensitive to these inhibitors. For instance,fumarate is a more potent inhibitor of the PHDs than FIH,
whereas citrate is a more potent inhibitor of FIH than the
PHDs [28,30]. Both fumarate and succinate reach very high
levels in hereditary cancers associated with the inactivation
of fumarate hydratase (FH, hereditary leiomyomatosis and
papillary renal cell carcinoma) and succinate dehydrogenase
(SDH, hereditary paraganglioma) respectively [31-33].
In these settings, fumarate and succinate clearly induce
HIF, at least in part by inhibiting the PHD enzymes [30].
However, whether and under what circumstances the
Krebs cycle and other metabolic intermediates reach the
levels required to inhibit the HIF hydroxylases in common
cancers is less clear.
Interestingly, a number of studies has demonstrated
that provision of glucose in cell culture medium and/or
on-going glucose metabolism is necessary for the induction
of HIF-1α by hypoxia [34]. Different investigators have pro-
vided evidence for a range of mechanisms. Provision of
lactate or pyruvate has been shown to stabilize HIF-1α in
glucose depleted cell cultures and it has been suggested that
this effect is mediated by inhibition of the PHDs by pyru-
vate produced from lactate by lactate dehydrogenase [35].
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and has also been proposed to activate HIF and vascular
endothelial growth factor (VEGF)-mediated angiogenesis in
cancer [36]. Oddly, neither pyruvate nor lactate was found
to compete with 2-OG or inhibit purified recombinant
PHDs under standard (ascorbate containing) reaction
conditions [28,29]. Some insight into this paradox may
be provided by recent work suggesting a different mode of
inhibition, whereby pyruvate and oxaloacetate inactivate
the PHDs by oxidation, which is reversed by ascorbate
[37]. Thus, metabolic intermediates have the potential to
inhibit the HIF hydroxylases by at least two mechanisms;
competition with 2-OG and oxidation.
Recently, interest has also focused on another ‘onco-
metabolite’, 2-hydroxyglutarate (2-HG), which has the
potential to competitively inhibit 2-OG dioxygenases.
Specific mutations in the genes encoding isocitrate de-
hydrogenases (IDH) 1 and 2 have been observed at a
high rate in low and medium grade gliomas, secondary
glioblastoma, acute myeloid leukemia, and at a lower
rate in other malignancies, including myelodysplastic syn-
dromes, T-cell lymphoma, chondrosarcoma and cholan-
giocarcinoma [38,39]. In affected cells, 2-HG is formed as
a result of reduction of 2-OG by the abnormal enzyme
and accumulates to very high levels [40]. However, 2-HG,
particularly the ‘R’ enantiomer that is formed by the
mutant IDH enzymes, is a poor inhibitor of the PHD
enzymes [41]. It is therefore unlikely to contribute to any
up-regulation of HIF that is observed in these settings and
has even been reported to activate PHD2, resulting in a
reduction in HIF [42].
In addition to effects of metabolites on the ‘oxygen
sensing’ hydroxylation reaction, multiple interactions of
metabolic and HIF signaling pathways have been defined
at other levels. For instance, HIF-α levels are subject to
complex translational controls operating through nutrient
and cellular energy-sensing mTOR complexes, with HIF-1α
being regulated through mTORC1 and 2, and HIF-2α
principally by mTORC2 [43]. In normal cells, several
mechanisms exist whereby hypoxia can reduce translation
either through mTOR pathways or via regulation of eIF2α
or eEF2. These pathways are themselves independent of
HIF and involve activation of AMPK or PERK in response
to metabolic changes arising from hypoxia [44]. However,
translational control can also be HIF-dependent. For
instance, HIF activates transcription of REDD1 [45], which
activates the tuberous sclerosis TSC1/2 tumor suppressor
complex [46], an upstream inhibitor of mTORC1. Cancer
cells can evade this down-regulation of HIF-α translation
at least in part through oncogenic dysregulation of mTOR
complexes.
Yet another interface with metabolism is mediated by
reversible acetylation at specific sites in HIF-α polypep-
tides. HIF-1α can be acetylated at multiple lysine residuesby acetyltransferases, such as p300/CBP associated fac-
tor (PCAF), and acetylation can be reversed by several
classes of enzyme, including classical histone deacetylases
(HDACs) and sirtuins [47-49]. Given their sensitivity
to another key parameter of energy status, the cellular
NAD+/NADH ratio, the interface between sirtuins and
HIF has attracted widespread interest. The mammalian
sirtuin family (SIRT1-SIRT7) of lysine deacetylases
couple deacetylation with NAD + hydrolysis. SIRT1, 3
and 6 have all been implicated in the regulation of HIF
activity [48,50-53], although there is disagreement as
to the exact nature of the interconnections. In one study,
deacetylation of HIF-1α at K674 by SIRT1 was reported to
block p300 recruitment by HIF-1α, with the inactivation
of SIRT1 in hypoxia (by decreased NAD+ levels) releasing
this negative control [48]. Another study has reported
SIRT1 activity to be required for full activity of HIF-1α in
hypoxia [53], while a third reports a specific functional
interaction between SIRT1 and HIF-2α leading to up-
regulation of HIF-2α transactivation in hypoxia [52].
SIRT1 itself is also reported to be a HIF target gene in
some [54], but not all, settings [53].
Iron, ascorbate and oxidant stresses
The binding of Fe(II) at the catalytic center of the HIF
hydroxylases, like that of other 2-OG dioxygenases, is rela-
tively labile. The enzymes also require ascorbate for main-
tenance of an active Fe(II) catalytic center. These properties
render them susceptible to modulation by redox signals
and iron availability, raising questions as to whether ab-
normalities in redox status and/or iron availability provide
another link between abnormal metabolism in rapidly
dividing cancer cells and activation of HIF.
In tissue culture, supplementation with either iron or
ascorbate promotes HIF hydroxylase activity and sup-
presses basal HIF levels in oxygenated cells [55]. Cancer
patients are often poorly nourished and systemic iron
deficiency is common [56]. Furthermore, rapid growth
and/or poor blood supply may exacerbate cellular iron
and ascorbate deficiencies within the tumor. Somewhat
surprisingly, the possibility that iron and ascorbate defi-
ciency may be important contributors to HIF activation
in clinical cancer has not been intensively investigated.
In scorbutic rodents, ascorbate supplementation did not
affect physiological measures of HIF activation, such as
the production of erythropoietin, suggesting that tissue
culture studies may not be representative of effects in the
intact organism [57]. Nevertheless, low cellular ascorbate
has recently been associated with increased HIF and aggres-
sive phenotype in clinical endometrial cancer [58].
The ability of both iron deficiency and redox stresses
to up-regulate HIF in tumors is strongly supported by
experimental studies. For instance, the suppression of iron
uptake by shRNA-mediated knockdown of transferrin
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angiogenesis in a breast cancer cell line xenograft model
[59]. In tumors derived from Ki-Ras transformed fibro-
blasts, activation of the antioxidant response by junD
has been reported to enhance PHD activity, reduce HIF
and impair angiogenesis [60]. In another xenograft model,
both ascorbate and the anti-oxidant N-acetylcysteine were
found to suppress HIF activation and growth of human
lymphoma cells through increased hydroxylation [61].
Kinetic studies on purified recombinant enzyme have
indicated that reducing agents other than ascorbate
can only partially substitute for ascorbate in activating
the HIF hydroxylases [62], and it is possible that in cells,
these agents are acting indirectly on processes that affect
cellular Fe(II) or ascorbate levels.
It has also been proposed that the increased produc-
tion of mitochondrial reactive oxygen species in hypoxia
contributes to HIF activation by impairing the activity of
HIF hydroxylases (reviewed in [63]). However, whether re-
duced activation of HIF following the application of mito-
chondrial inhibitors arises from a reduction in reactive
oxygen species, or an increase in intracellular oxygen levels
(as a result of reduced mitochondrial oxygen consumption)
is controversial (reviewed in [64]). Interestingly, HIF aspara-
ginyl hydroxylation is much more sensitive to inhibition
by hydrogen peroxide than HIF prolyl hydroxylation [65],
whereas the reverse is true for inhibition by hypoxia [66].
This suggests that hypoxia and reactive oxygen species
affect HIF signaling by distinct mechanisms. Since HIF
asparaginyl hydroxylation persists under all but the most
severe levels of hypoxia [66] and specifically modulates
the expression of some but not all HIF target genes [67],
these findings also suggest that interplay between hypoxia
and redox signals in tumors not only activates HIF, but
shapes the nature of the HIF transcriptional response.
In addition to modulation of HIF hydroxylase activ-
ity, redox signals and oxidant stress (such as metabolic
dysregulation) impinge on the HIF pathway at many
other levels. Effects are observed on both transcription
and translation of individual HIF-α isoforms. For instance,
the HIF-1α promoter contains a well characterized nuclear
factor kappa B (NF-kB) binding site that conveys up-
regulation by oxidant stresses [68], while HIF-1β tran-
scription can also be activated directly by NF-kB [69].
Studies of the effects of nicotinamide adenine dinucleo-
tide phosphate (NADPH) oxidases in pVHL-defective
renal cancer cell lines (in which the pVHL-dependent
proteolysis is disrupted) suggest several other levels of
control. For instance, NADPH oxidase, specifically Nox4,
was found to elevate HIF-2α mRNA levels [70], whereas
NADPH oxidase-dependent generation of reactive oxygen
species has been proposed to enhance translation of
HIF-2α [71]. Taken together, these findings reveal multiple
interactions with redox signals that have the potential toaffect both quantitative and qualitative aspects of HIF
pathway activation in cancer.
Oncogenic and tumor suppressor pathways
In addition to activation by multiple micro-environmental
stimuli, the HIF system is activated by diverse tumor
suppressor and oncogene pathways. The most striking
of these is mutation of the von Hippel-Lindau tumor
(VHL) suppressor (reviewed in [72]). As outlined above,
pVHL is part of the ubiquitin E3 ligase complex that targets
HIF-α subunits to the ubiquitin-proteasome pathway.
Biallelic inactivation of VHL thus blocks oxygen-dependent
proteolysis of HIF-α and leads to constitutive activation
of the HIF pathway. Interestingly, however, more detailed
analysis of HIF in pVHL-associated cancer has revealed the
importance of quantitative effects on HIF activation. In par-
ticular, there is a clear correlation between the quantitative
effects of specific mutations on HIF dysregulation and
the prevalence of different types of neoplasia in families
affected by VHL disease [73,74]. Severe dysregulation of
HIF is associated with a predisposition to renal cancer,
but appears to be incompatible with pVHL-associated
phaeochromocytoma, which is associated with partially
inactivating mutations that lead to more modest levels
of HIF pathway activation.
HIF is also activated by a range of growth factors acting
through PI3K/PTEN/AKT or RAS/RAF/MAPK signaling
cascades (reviewed in [75]). Activation of these pathways
by somatic mutation and gene amplification is common
in many types of cancer and dysregulation of the PI3K/
PTEN/AKT pathway leads to up-regulation of HIF
through increased synthesis of HIF-α subunits [76].
The AKT serine/threonine kinase has multiple down-
stream targets, and likely increases HIF-α translation by
both mTOR-dependent and mTOR-independent mech-
anisms [77]. It is also possible that AKT may increase
HIF-α levels through other mechanisms. For example,
another substrate of AKT, GSK3b, has been implicated
in regulating HIF-1α protein degradation through a pVHL
independent mechanism [78].
The RAS/RAF/MAPK pathway has been reported to
impact on HIF activity primarily through the regulation
of transactivation. Phosphorylation of either HIF-1α or
the co-activator p300 by different kinases (either p42/
p44 MAPK or p38) activates HIF, both by promoting
the formation of HIF/p300 complexes and by enhancing
p300 transactivation [79].
Diverse interactions between HIF and p53 tumor sup-
pressor pathways have been reported (reviewed in [80,81]).
Though not all reports are in agreement, the induction
of p53 has generally been shown to suppress HIF activity.
Both direct physical interactions between p53 and HIF-1α
[82] and indirect functional interactions have been de-
scribed, including competition between p53 and HIF-α for
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of HIF-α degradation by the mouse double minute 2 homo-
log (MDM2) ubiquitin-ligase [84].
Genetic mutation
In contrast with the prevalence of mutations in classical
tumor suppressor and oncogenic pathways that are linked
to the HIF system, direct mutational activation of HIF
(for example, by deletion or mutation of key residues
in the degradation domain) is not common in cancer.
Rather, in pVHL-defective renal cancer, a small but signifi-
cant excess of inactivating mutations has been observed in
HIF-1α and reduction in HIF-1α gene dosage through
deletion of a region of chromosome 14q is common
[85-87]. Inactivating mutations in the HIF hydroxylases
are also uncommon in cancer.
Taken together these findings reveal a plethora of means
and mechanisms by which both micro-environmental and
genetic alterations lead to the up-regulation of HIF in can-
cer. However, they also demonstrate a remarkable contrast
between the low prevalence of cancer-associated activating
mutations in HIF itself and the high prevalence of muta-
tions in multiple oncogenes and tumor suppressor genes
whose products impinge on the activity of the pathway.
Regulation of metabolism by HIF
Glycolysis
Following the identification of genes encoding glycolytic
enzymes as the first non-erythropoietin targets of the
HIF system [10,11] the role of HIF in the glycolytic path-
way has been extensively studied, at least at the level of
gene expression. These studies have established an action
of HIF at almost every step in glycolysis. Both the specific
glucose transporters necessary for the initial glucose
internalization, and monocarboxylic acid transporters
that promote lactate efflux, have been identified as HIF-1
target genes [88,89]. Thus, HIF impacts on both the glyco-
lytic pathway itself and on the ancillary processes that sup-
port it. HIF-dependent transcription is strikingly isoform or
isoenzyme specific. For instance, hypoxia up-regulates
lactate dehydrogenase A and monocarboxylate transporter
4 (which act to promote conversion of pyruvate to lactate
and lactate efflux from the cell), but down-regulates
monocarboxylate transporter 1 and lactate dehydrogenase
B (which act to promote lactate uptake and conversion to
pyruvate in the reverse direction) [89].
The glycolytic isoenzymes that are up-regulated by HIF
are remarkably similar to those that are over-expressed in
cancer cells. In general, they have kinetic properties that
enhance flux through particular components of the glyco-
lytic pathway, or are less sensitive to inhibitory regulators
(reviewed in [90]). This is illustrated by 6-phosphofructo-
1-kinase (PFK-1), which catalyzes a key regulatory step
in glycolysis, conversion of fructose-6-P to fructose-1,6-bisphosphate. PFK-1 exists as three isoforms (PFK-L, -P
and -M), which differ in their sensitivity to feedback
inhibition by ATP and the Krebs cycle intermediate cit-
rate. The PFK-L isoform, which is the principal isoform
up-regulated by HIF, is the least sensitive to these in-
hibitors. However, although PFK-L is up-regulated by
HIF-1, its activity remains allosterically controlled by
fructose-2,6-bisphosphate, the product of a dual kinase/
phosphatase family of enzymes (6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 1-4, PFKFB1-4). Binding
of fructose-2,6-bisphosphate promotes PFK tetramer
formation and increases catalytic activity. HIF-1 also
induces expression of PFKFB enzymes; in particular,
the PFKFB-3/4 isoforms that have a high ratio of kinase
to phosphatase activity and hence increase fructose-2,6-
bisphosphate levels [91]. Yet further complexity is added
by post-translational regulation of the ability of PFK-1
to bind fructose-2,6-bisphosphate. Glycosylation (O-linked
β-N-acetylglucosamine) at serine 529 prevents binding of
fructose-2,6-bisphosphate, inhibits activity of PFK-1, and
is proposed to redirect flux to the biosynthetic pentose
phosphate pathway [92]. Although the role of HIF was not
studied, glycosylation at serine 529 was reported to be
strongly induced by hypoxia, apparently opposing the effect
of HIF in inducing fructose-2,6-bisphosphate levels.
Another important regulatory enzyme is pyruvate kinase.
Pyruvate kinase catalyzes the terminal step in glycoly-
sis, and is therefore well placed to alter the metabolic
fate of glucose: either to maximize ATP generation; or
to slow glycolysis, resulting in a build-up of glycolytic
intermediates that supply biosynthetic pathways. HIF-1
induces transcription of the PKM gene [93]. However
cancer cells replace the normal form of pyruvate kinase
(PKM1) with an alternatively spliced embryonic form
(PKM2) which is less active. The conversion to PKM2
alters the residues within the major inter-subunit con-
tact domain [94] and makes PKM2 activity more readily
down-regulated by reversible subunit dissociation from
active tetramer to inactive dimer. The switch to PKM2
also facilitates catalysis of phosphoenolpyruvate (PEP)-
dependent histidine phosphorylation of the upstream
enzyme phosphoglycerate mutase-1 (PGAM-1), which
increases PGAM-1 activity and is again proposed to redir-
ect glycolytic flux away from ATP synthesis and into the
production of biosynthetic intermediates [95]. Interestingly,
the role of PKM2 in supporting cancer growth appears
to be highly context specific. Indeed, knockdown of PKM2
yielded contradictory results in xenograft tumor models
[96,97] and a recent study of tumorigenesis in mice has re-
vealed that while PKM2 isoform specific deletion enhances
tumor growth, it also appears to select against outgrowth of
tissue culture cell lines from the tumors [98]. Whether HIF
is involved in the alternative splicing process that switches
PKM1 to PKM2, as opposed to up-regulation of the primary
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different, but specific, interaction of PKM2 with the HIF
system has been proposed in a recent report describing
a non-glycolytic role of PKM2 in the transcriptional
co-activation of HIF-1α, potentially driving a positive
reinforcing circuit [93].
Taken together with the proposed action of glycolytic
intermediates in the regulation of HIF, these findings
indicate the existence of an extremely complex interplay
between the HIF pathway and glycolysis. However, rela-
tively few studies have actually measured HIF-dependent
changes in metabolic fluxes, as opposed to levels of en-
zymes and regulators. Studies of transformed mouse
embryonic fibroblasts have demonstrated that in hypoxic
culture, inactivation of HIF-1α is associated with reduced
lactate production and impaired maintenance of ATP levels
[99]. Thus, down-regulation of HIF by oxygen appears, at
least in part, to contribute to the ‘Pasteur effect’ in mamma-
lian cells (down-regulation of fermentation in the presence
of oxygen). Interestingly, however, these studies did not
reveal an effect of HIF-inactivation on lactate production
in normoxic cells. Similarly, recent metabolic profiling of
Hct116 colon cancer cells revealed that while siRNA medi-
ated knock-down of HIF-1β reduced hypoxic up-regulation
of lactate production, it did not reduce glucose uptake in ei-
ther normoxic or hypoxic cells [100]. Furthermore, studies
of HIF-1β deficient hepatoma cells have revealed that glyco-
lytic flux as assessed by FDG-PET analysis of glucose up-
take and by measurement of lactate output was maintained,
despite down-regulation of multiple glycolytic genes in
the absence of HIF. Further analysis indicated that the
enhanced glycolytic flux was associated with allosteric
activation of PFK-1 by an increase in the AMP/ATP ratio
in the HIF-1β deficient cells [101].
Thus, although the activation of HIF in cancer cells
and the action of HIF on specific glycolytic enzymes,
regulators and transporters would all suggest that HIF
makes an important contribution to the Warburg effect,
intervention studies have revealed that up-regulated gly-
colysis continues at least in some settings in the absence
of HIF. Studies of the action of tumor suppressors and on-
cogenes have revealed multiple direct interfaces with the
regulation of glycolysis and parallel pathways of oncogenic
glycolytic activation, presumably accounting for these ob-
servations. Nevertheless, the isoenzyme specific targeting
by HIF of essentially every point in the glycolytic pathway
strongly suggests that HIF contributes, albeit through par-
allel pathways, to the up-regulation of glycolysis in cancer.
Pentose phosphate pathway
In most cells, in addition to entering glycolysis, glucose-6-
phosphate can also be metabolized by the pentose phos-
phate pathway which, through a series of cytoplasmic
reactions, generates NADPH (used in reductive synthesisof fatty acids and sterols), ribose-5- phosphate (used in
synthesis of nucleotides and nucleic acids) and other
biosynthetic intermediates. Ribose-5-phosphate has
been identified in metabolic profiling of cancer cells as
one of the most strongly up-regulated metabolites in
hypoxia [100]. Whether this reflects changes that limit
flux through glycolysis, such as glycosylation of PFK-1
(see above) or changes in the pentose phosphate path-
way itself is unclear. Interestingly, however, glucose-6-
phosphate dehydrogenase, the enzyme which catalyzes
the entry step to the pentose-phosphate pathway, is
up-regulated by hypoxia in at least some cancer cells,
though whether this is as a response to HIF has not
been resolved [102].
Glycogen metabolism
Studies of glycogen metabolism also support a key role
for HIF in biosynthetic metabolic pathways that are
dysregulated in cancer. Increased storage of glycogen
is a common feature of cancer cells, which, along with
lipid deposition, contributes to the clear cell phenotype
in some tumors. As with the glycolysis, enzymes catalyzing
multiple steps in glycogen biosynthesis have been identi-
fied as HIF target genes, including phosphoglucomutase 1
(the first enzyme in the pathway), UDP-glucose pyrophos-
phorylase 2 (which forms UDP-glucose, the direct precur-
sor of glycogen), glycogen synthase and glucan (1,4-alpha-),
branching enzyme 1 [103,104]. HIF-dependent induction of
these targets has been demonstrated to produce striking in-
creases in glycogen deposition during hypoxic culture.
In terms of energy balance, the stimulation of energy
storage by hypoxia appears paradoxical. It has been sug-
gested to be an adaptive response to the future threat of
energy starvation and the response does indeed enhance
survival during adverse growth conditions [103,104]. Inter-
estingly, however, the glycogen degradation enzyme glyco-
gen phosphorylase (PYGL) is also induced by hypoxia,
but over a longer time-scale than the synthetic enzymes
[105]. Inhibition of PYGL activity was demonstrated to
have striking effects on tumor cell viability, inducing senes-
cence, and markedly impairing experimental tumor growth.
Metabolic flux analysis revealed that PGYL knock-down
impaired flux into the pentose phosphate pathway and gen-
eration of NADPH. The authors suggest that a critical role
in redox regulation and/or provision of biosynthetic inter-
mediates is more likely than simple lack of energy provision
to explain such major effects of PYGL knock-down on cell
viability [105].
Lipid metabolism
Abnormal lipid synthesis is yet another biosynthetic cancer
phenotype that interfaces with hypoxia and HIF. Increased
lipid content is a common feature of cancer cells and
in some tumors large accumulations contribute to the
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the reasons why such large stores accumulate are not
clear, though the two phenomena appear to be linked.
For instance, both lipid and glycogen accumulate in
clear cell renal carcinoma cells, where defective pVHL
leads to constitutive activation of HIF. Whereas the
clear cell phenotype is lost in normal culture medium,
growth in adipogenic medium promotes accumulation
of glycogen as well as lipid [106].
Despite the high energy costs (14 ATP and 7 NADPH
for each molecule of the 16-carbon fatty acid, palmitate),
lipid accumulation in cancer clearly involves increased
de novo fatty acid synthesis [107]. In this process, cyto-
plasmic acetyl CoA is first converted to malonyl CoA by
acetyl CoA carboxylase. Fatty acids are then produced
by successive additions of malonyl CoA to the carbon
chain, catalyzed by fatty acid synthase (FAS). Up-regulation
of FAS correlates strongly with aggressive malignancy,
and inhibition of FAS rapidly inhibits cancer cell prolifera-
tion, inducing cell-cycle arrest and apoptosis [108,109]
(for review see [110]). Lipid synthesis potentially provides a
resource for the production of new membrane and lipid
signaling molecules that are important for cell proliferation.
In keeping with this, synthesis of a very wide range of lipid
molecules, including different types of phospholipid, chol-
esterol and lipid hormones, prostaglandins, leukotrienes
and sphingolipids as well as fatty acids have been reported
to be up-regulated in cancer. Remarkably, hypoxia appears
to promote many of these synthetic pathways as well as
promoting cellular lipid uptake, with interactions between
lipid and hypoxia signaling pathways occurring at multiple
levels [111,112]. Multiple effects on lipid synthesis gene ex-
pression patterns are apparent from large-scale pathway
analyses. For instance, an extensive adipose gene expression
signature is present in pVHL-defective cancer, where HIF is
constitutively activated [106]. Key individual genes in lipid
metabolism have also been reported to be strongly induced
by hypoxia. For instance, both the cytosolic form of
acetyl-CoA synthetase, which generates acetyl-CoA for
fatty acid synthesis in the cytosol and FAS itself are in-
duced in hypoxic tissue culture, while in tumors, spatial
patterns of FAS expression coincide with hypoxia markers
[113]. Other studies have identified hypoxia inducible
genes involved in highly diverse processes in lipid biology.
Examples include molecules with functions in lipid drop-
let formation (hypoxia-inducible protein 2), prostaglandin
biosynthesis (cyclooxygenase 2), lipid signaling systems
(lipoxygenase 12-lox, sphingosine kinase, SphK1) and
synthetic processes (stearoyl-CoA desaturase-1, a rate-
limiting enzyme in the biosynthesis of monounsaturated
fatty acids) [114-117].
Though some of these genes are direct HIF transcrip-
tional targets, in others up-regulation is mediated indirectly
by an action of HIF on transcription factors that regulatelipid metabolism or adipose differentiation programs.
Thus, in different settings, HIF-1 has been reported to
down-regulate peroxisome proliferator-activated receptor
(PPAR)-α and either to up-regulate or down-regulate
PPAR-γ [118-120]. Hypoxia also interacts with many other
transcriptional networks, including sterol response element
binding proteins (SREBPs), DEC1/2 and GATA2/3 that
act on key targets in lipid metabolism. For instance, hyp-
oxic induction of FAS appears to involve HIF-dependent
up-regulation of SREBP1 and an action of SREBP1 on the
promoter of FAS [113].
Altered lipid fluxes may also occur from the effects of
hypoxia on pathways that provide intermediates for lipid
synthesis (Figure 3). Thus, at least in some hypoxic settings,
reduced production of acetyl-CoA by pyruvate dehydro-
genase (see below) impairs fatty acid synthesis from
glucose. Normally, acetyl CoA that is generated in the
mitochondrion by pyruvate dehydrogenase is converted to
citrate by the Krebs cycle enzyme citrate synthase. When in
excess, citrate can then be transported out to the cytoplasm
and converted back to acetyl CoA by ATP-citrate lyase.
Cytoplasmic acetyl CoA is then used in lipid biosynthesis.
However, in hypoxic cancer cells, where the flow of glucose
metabolites through this pathway is reduced, metabolism of
glutamine can compensate to maintain the supply of cyto-
plasmic acetyl CoA. Metabolic flux studies have revealed
that this occurs through the operation of the mitochondrial
enzyme isocitrate dehydrogenase 2 (IDH2) in the reverse
direction from the Krebs cycle generating citrate by reduc-
tive carboxylation of 2-OG derived from glutamine [121].
An additional cytoplasmic route of reductive carboxylation
is mediated by IDH1 [122,123]. These pathways provide
cytoplasmic acetyl CoA following the action of ATP-citrate
lyase and metabolic flux analyses have demonstrated that
the glutamine-driven reductive carboxylation is increased
by hypoxia and is dependent on HIF [122]. Exactly how
HIF stimulates reductive carboxylation remains unclear,
but studies of HIF-α knock-down in pVHL-defective renal
carcinoma cells demonstrate dependence on HIF-1α and/
or HIF-2α, [121,122] leading to a reduction in intracellular
citrate levels [124].
Mitochondrial metabolism
In a process that reflects its role in oxygen homeostasis,
HIF down-regulates mitochondrial oxidative phosphor-
ylation through a range of actions on mitochondrial me-
tabolism and biogenesis.
In the presence of oxygen, pyruvate produced from
glycolysis is converted to acetyl CoA in the mitochondrial
matrix by pyruvate dehydrogenase complex (PDH), pro-
viding substrate for the Krebs cycle. Activity of the PDH
is regulated by phosphorylation catalyzed by pyruvate
dehydrogenase kinase (PDK) isoforms 1 to 4 and pyruvate

























































































Figure 3 Schematic illustrating the action of HIF on multiple aspects of cellular metabolism.
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duction of PDK1 leads to PDH inhibition, thus disconnect-
ing the Krebs cycle from glycolysis (Figure 3) [125,126].
Mitochondrial function can also be attenuated by the
HIF-dependent down-regulation of the activity of several
components of the electron transport chain. For example,
complex 1 activity has been reported to be inhibited as
a result of HIF-1-dependent activation of NADH dehydro-
genase [ubiquinone] 1 alpha sub-complex 4-like 2, NDU-
FA4L2 [127]. Complex 2, the succinate dehydrogenase
(SDH) complex (SDHA, B, C and D) also exhibits reduced
activity in response to hypoxia. The exact mechanism is un-
clear, but is reported to involve a HIF-1 dependent reduc-
tion in SDHB protein levels through a post-transcriptional
mechanism [128]. The last enzyme in the electron transport
chain, cytochrome c oxidase (COX), is also a target for
HIF-dependent regulation. Two of its regulatory subunits
exhibit differential regulation by HIF, allowing a switch to
a subunit composition that is better adapted to hypoxia:
COX4-2 is a HIF transcriptional target and is up-regulated
in hypoxia; whereas the COX4-1 subunit is down-regulated
by an indirect mechanism achieved (at least in part) by theHIF-dependent activation of the mitochondrial LON prote-
ase that degrades COX4-1 [129]. HIF-dependent effects on
mitochondrial function and the electron transport chain
may also be achieved by indirect mechanisms. For instance,
transcriptional activation of the micro-RNA miR-210 by
HIF leads to a down-regulation of multiple targets im-
portant for mitochondrial function, including NDUFA4,
SDHD, the iron-sulfur cluster assembly proteins ISCU1/2
and the COX assembly protein COX10 [130,131].
Finally, HIF can influence mitochondrial function
through effects at the whole organelle level. Studies in
the pVHL-defective renal carcinoma cell line RCC4 have
shown that HIF can suppress mitochondrial respiration and
mitochondrial mass through negative regulation of c-MYC,
the activity of which promotes mitochondrial biogenesis
[132]. Cross-talk between HIF and MYC has been defined
at a number of levels, including co-operation and compe-
tition at DNA-binding sites, non-DNA binding interaction
between specific HIF-α isoforms and MYC subunits,
and interactions mediated by expression of the HIF tar-
get gene MXI-1, which represses c-MYC activity [132]. In
addition, the HIF target gene BNIP3 contributes to reduced
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autophagy [133].
Overall, these effects of HIF cause an adaptive shift away
from mitochondrial respiration. Together with preservation
of biosynthetic capacity, through the generation of citrate
by reductive carboxylation, this conveys survival advantages
in hypoxia. HIF-1α defective cells are unable to down-
regulate oxygen consumption in the face of hypoxia and
show impaired survival in hypoxia, at least in part due to
an enhanced production of reactive oxygen species [129].
Conclusions
Overall these studies have defined multiple means by which
HIF is up-regulated in cancer (Figure 2) and multiple ef-
fects of HIF activation on metabolism in cancer (Figure 3).
Furthermore, although HIF acts (directly or indirectly) on
genes encoding a wide range of enzymes that contribute
to metabolic dysregulation in cancer, many of these en-
zymes are also direct targets of the oncogenic pathways.
For instance, activation of PI3K/PTEN/AKT signaling
activates HIF and, hence, indirectly activates transcription
of genes encoding multiple glycolytic enzymes. However,
AKT activation also directly up-regulates glucose me-
tabolism via a range of other mechanisms, including the
increased expression [134] and trafficking of glucose
transporters to the cell membrane [135,136], increased
expression of glycolytic enzymes and altered phosphoryl-
ation of regulatory components, such as PFKFB2 [137-139].
The parallel operation of these complex pathways makes
the non-redundant role of any one molecular connection
difficult to predict. Unsurprisingly, given that HIF is pri-
marily a transcription factor, the large majority of studies
have focused on the effects on gene expression and there
are relatively few studies of the effect of HIF on specific
metabolic fluxes. However, key enzyme activities are
regulated at many levels other than gene expression,
and altered metabolism requires coordinated changes
in the function of many enzymes. Therefore, overall effects
on metabolic fluxes are difficult to derive from the
measurement of gene expression levels, and more direct
assessments of the effects of HIF activation on fluxes
through different metabolic pathways would be useful.
Despite this caveat, it is clear that HIF contributes to
very many aspects of dysregulated metabolism in cancer
cells. Given the diversity of these effects, an important, but
as yet incompletely answered question, concerns the extent
to which the effects of HIF activation and oncogenic activa-
tion coincide on the same metabolic pathways.
The most obvious difference between the effects of HIF
activation and those of oncogenic pathways is apparent in
the actions on mitochondrial function. HIF activation
down-regulates mitochondrial biogenesis and mitochon-
drial metabolism, whereas oncogenic pathways generally
have the reverse effect, promoting mitochondrial metaboliccapacity by multiple mechanisms (reviewed in [140,141]).
As mitochondrial metabolism is the main component of
cellular oxygen consumption, this action of HIF to reduce
oxygen consumption in the face of hypoxia can be ratio-
nalized in terms of the central role of HIF in maintaining
oxygen homeostasis and it has been proposed that, in this
setting, HIF acts to tune the metabolic dysregulation in
cancer in accordance with availability of oxygen.
In contrast with effects on mitochondrial metabolism,
a wide range of other metabolic functions manifest close
similarities between the effects of HIF activation and those
of activated oncogenic pathways. The concordance between
the isoforms of glycolytic enzymes that are up-regulated
by HIF, and those that are targeted directly by oncogenic
pathways is striking. Also remarkable is the concordance
between the activation of biosynthetic pathways involving
excess glycogen and lipid production, by both HIF and ac-
tivated oncogenic pathways. Enhanced production of ATP
by glycolysis in hypoxic cells is clearly consistent with the
maintenance of oxygen homeostasis. However, the pattern
of glycolytic enzyme isoform activation that is induced
both by HIF and by oncogenic pathways is not such as
to maximize ATP production, and a large body of evi-
dence suggests that its prime function is the supply of
biosynthetic intermediates. Similarly, activation of both
glycogen synthesis and lipid biosynthesis (again by both
HIF and oncogenic pathways) is hypothesized to reflect the
needs of proliferating cells for biosynthetic intermediates
(reviewed in [110,142]). Since these processes neither re-
duce oxygen demand, nor increase oxygen supply, it is not
at all clear how these effects relate to the concept of HIF
as a regulator of oxygen homeostasis. Thus it may be neces-
sary to revise thinking on the prime function of the HIF
system to include general support of growth/repair path-
ways (perhaps as a response to hypoxic tissue damage)
as opposed to more restricted growth pathways, such
as angiogenesis or erythropoiesis, that directly enhance
oxygen delivery.
Whatever the explanation, a large body of evidence
implicates HIF in the up-regulation of biosynthetic path-
ways that support the growth of cancer cells while multiple
genetic and micro-environmental alterations promote
the up-regulation of HIF in cancer. Given the compelling
associations between HIF activation, aggressive phenotypes
and adverse prognosis across different types of cancer,
it is tempting to conclude that activation of HIF is not
only a major contributor to the cancer phenotype, but that
it is causally implicated in cancer progression. Surpris-
ingly, while mechanistic analysis strongly supports the first
of these statements, there is a striking absence of human
genetic evidence to support the second. As outlined above,
cancer genome analyses have not yet defined clusters of
mutations typical of oncogenic activation in genes en-
coding any HIF subunit; to date the clearest evidence
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of inactivating mutations in HIF-1α in the context of
pVHL-defective renal cancer (reviewed in [143]).
The ‘co-selection’ hypothesis
We have previously drawn attention to this paradox
and argued that the extraordinarily strong association
between HIF activation and aggressive cancer most likely
reflects the existence of ‘hard-wired’ pathways that operate
physiologically to link tissue growth to oxygen supply and
are, therefore, ‘co-selected’ by oncogenic pathways that
drive cellular proliferation directly [144]. An important
implication of this ‘co-selection’ hypothesis is that the
very extensive connections of the HIF transcriptional
cascade will all be ‘co-selected’ into the cancer phenotype
(by both oncogenic or micro-environmental activation of
HIF), irrespective of whether they are promoting or restrict-
ing cancer growth. Although many aspects of HIF activa-
tion may contribute to cancer development, the existence
of cytostatic responses that form part of the physiological
response to hypoxia may have the reverse effect, possibly
accounting for the observation that HIF-1α displays some
of the characteristics of a tumor suppressor, at least in
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ing the interface between HIF activation and metabolic dys-
regulation in cancer, an important question is how far do
similar arguments extend to the massively complex HIF-
dependent and HIF-independent pathways that underpin
metabolic dysregulation in cancer?
A key advance in the understanding of cancer metabol-
ism has been the recognition that dysregulated metabolic
pathways are not simply responding to error signals, such
as metabolite depletion created within the tumor mass, but
(as with HIF), are directly connected to oncogenic signaling
pathways [145,146]. Furthermore, like HIF, a similar genetic
paradox exists. Although gene amplification events have
been described for a number of metabolic enzymes that are
over-expressed or activated in cancer [146], for most meta-
bolic pathways whose up-regulation is strikingly associated
with aggressive cancer, there is an apparent paucity of
mutations that directly activate the pathway. Interestingly,
this paradox has been brought into even sharper focus by
the striking mutational profiles that do exist in very specific
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[30-32], and in the IDH1 and 2 oncogenes.
The mutational profile of IDH1 and 2 is particularly
informative. Multiple different substitutions are observed
at highly specific substrate binding residues in each gene,
but not elsewhere. These mutations are heterozygous and
conform to the classical expectations of an oncogene
(acting dominantly to promote cancer) and strong evidence
has been assembled for their oncogenic action through
the production of 2-HG [40]. Evidence for the proposed
action of 2-HG on 2-OG-dependent dioxygenases that
are involved in epigenetic regulation or other potential
oncogenic pathways has been reviewed elsewhere [147].
What is important for the current discussion is that the
IDH1/2 mutational profile acts as a striking positive
control, emphasizing the extraordinary capacity of hu-
man cancer to ‘purify’ mutations that do provide select-
ive advantage. Against this background, the relative lack
of activating mutations in enzymes belonging to other
metabolic pathways that are up-regulated in cancer is
striking. As with HIF, this contrasts markedly with the
numerous connections that have been defined between
metabolic enzymes and mutated oncogenes. Thus, it ap-
pears likely that co-selection of ‘hard-wired’ metabolic
pathways that exist physiologically to support dividing
cells may therefore extend to both HIF-dependent and
HIF-independent pathways underpinning dysregulated
metabolism in cancer (Figure 4). Though multiple inter-
vention studies support the positive contributions of
metabolic dysregulation to cancer growth and, hence, the
possibility that these pathways represent potential targets
for anti-cancer treatment [105,148], the ‘co-selection’
hypothesis implies that this cannot be inferred directly
from the strong association with aggressive malignancy,
and that direct testing in the context of specific cancers
will be required.
In an extension of this argument, co-selection may
explain one otherwise puzzling aspect of dysregulated
cancer metabolism, the occasional generation of bizarre
cellular phenotypes by apparently excessive accumulation
of energy stores. As outlined above, increased glycogen
and lipid biosynthesis are common features of cancer cells.
While activation of these processes can be rationalized in
terms of provision of biosynthetic intermediates necessary
for cellular growth, it is much more difficult to understand
how the massive accumulation of glycogen and lipid asso-
ciated with the ‘clear cell’ phenotype in certain cancers
assists cancer growth. Similar arguments apply to cancer-
associated angiogenesis. The entrainment of an oxygen
supply through effective angiogenesis is clearly important
for cancer growth, but the bizarre and ineffective excessive
angiogenic activity that is often observed in tumors is more
difficult to understand, particularly under the hypothesis
that up-regulation of angiogenesis is directly selected. Wepropose that both may represent the effects of ‘co-selecting’
circuits that are ‘hard-wired’ to oncogene activation to
support the needs of growing tissues. Under physiological
conditions these pathways are tightly regulated so that en-
hanced ‘metabolic’ and ‘angiogenic’ activity is well coordi-
nated with cellular growth. In cancer these processes are
also, in general, fairly well coordinated, so as to entrain
broadly functional metabolic and angiogenic support
pathways. However, review of the mechanisms and
pathways leading to HIF activation in cancer reveals
mechanisms that are qualitatively and quantitatively
diverse. Thus, the stochastic activation of individual
oncogenic pathways by genetic mutations conferring se-
lection through cell autonomous advantage also has the
potential to create disorganized and chaotic activation
of metabolic and angiogenic pathways, dependent on
the nature of the pre-existing link between the affected
oncogene and metabolic/angiogenic pathways. For in-
stance, whereas under some circumstances pathway
activation may be inadequate to support cancer growth
(for example, poorly angiogenic tumors), under other
circumstances (for example, massive stores of glycogen and
lipid and exaggerated angiogenesis associated with powerful
and direct activation of HIF in pVHL-defective tumors), it
is excessive (Figure 4).
In summary, work on the HIF pathway has revealed
massively complex interactive connections between cancer
growth and HIF activation and between HIF activation
and cancer phenotypes. We argue that one of the most
important and, so far, under-appreciated implications
of these findings is the need to consider the implication of
co-selecting massive hard-wired physiological pathways as
cancer progresses. Though we have reviewed this consider-
ation from the perspective of HIF (where the ease with
which cells can be exposed to the physiological stimulus of
hypoxia has led to a rapid appreciation of the enormous
complexity of the pathway), similar considerations are likely
to apply to other pathways that may be activated by micro-
environmental stress or genetic mutation in cancer.
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